Trial Profile

A Clinical Trial to Evaluate LY03013 for the Treatment of Alzheimer's Disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Sep 2020 According to a Luye Pharma Group media release, the company has received the approval from the Center for Drug Evaluation of China to begin this trial.
25 Jun 2020 New trial record
19 Jun 2020 According to a Luye Pharma Group media release, the Investigational New Drug application for Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD, LY03013) has been formally accepted by the Center for Drug Evaluation of the National Medical Products Administration in China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com